|
Mr. Sanders assumed responsibility as COO in April 2008 after heading Genta's sales & marketing and worldwide commercial operations for 2 years. Prior to joining Genta, Mr. Sanders held key senior leadership positions in the commercial organizations of Pharmacia (now P?zer), Sano?-Synthelabo and subsequently Sano?-Aventis. He served at the Vice-President level within the Oncology commercial organizations of Sano?-Aventis and Sano?-Synthelabo. In those roles, he had key responsibilities for the commercial success of Eloxatin® (oxaliplatin), Taxotere® (docetaxel), Anzemet® (dolasetron mesylate), and ELITEK® (rasburicase). He led the successful restructuring, integration, deployment, strategic development, and tactical execution of the merged companies' sales forces. He was responsible for national account GPO contracting strategy and negotiations, and he shared responsibility for oncology sales training and sales operations. At Sano?-Synthelabo, he led the 110-member team that achieved record sales for an oncology product launch with Eloxatin® (oxaliplatin). From 1987 until 2002, Mr. Sanders held progressively increasing levels of responsibility at Pharmacia, Inc. (now P?zer) participating in the launches of Camptosar® (irinotecan) and ELLENCE® (epirubicin). Mr. Sanders holds a Bachelor of Business Administration from Memphis State University. | 